Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study

被引:32
作者
Afif, Waqqas [1 ,2 ]
Sandborn, William J. [1 ,3 ]
Faubion, William A. [1 ]
Rahman, Meher [4 ]
Harmsen, Scott W. [5 ]
Zinsmeister, Alan R. [5 ]
Loftus, Edward V., Jr. [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] McGill Univ, Div Gastroenterol & Hepatol, Ctr Hlth, Montreal, PQ, Canada
[3] Univ Calif San Diego, Div Gastroenterol & Hepatol, La Jolla, CA 92093 USA
[4] Mayo Clin Hlth Syst, Immanuel St Josephs Specialty Clin, Gastroenterol Sect, Mankato, MN USA
[5] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA
关键词
lymphoma; immunosuppressive; anti-TNF-alpha; EPSTEIN-BARR-VIRUS; CROHNS-DISEASE; LYMPHOPROLIFERATIVE DISORDERS; RHEUMATOID-ARTHRITIS; ULCERATIVE-COLITIS; AZATHIOPRINE; THERAPY; INFLIXIMAB; IMMUNOSUPPRESSION; 6-MERCAPTOPURINE;
D O I
10.1097/MIB.0b013e318281325e
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background:Subgroups of patients with inflammatory bowel disease (IBD) may have an increased risk of developing lymphoma. We sought to identify factors that were associated with lymphoma in patients with IBD.Methods:Cases and controls were identified through a centralized diagnostic index. We identified 80 adult patients with IBD who developed lymphoma between 1980 and 2009. For each case, 2 controls were matched for subtype of IBD, geographic location, and length of follow-up. Conditional logistical regression was used to assess associations between risk factors and the development of lymphoma.Results:Sixty patients were males (75%) versus 77 controls (48%). Median age at index date was 59 years for cases and 42 years for controls. Twenty patients (25%) and 23 controls (14%) were receiving immunosuppressive medications at the index date. Four patients (5%) and 6 controls (4%) were receiving anti-tumor necrosis factor agents at the index date. In multiple variable analysis, age per decade (odds ratio, 1.83; 95% confidence interval, 1.37-2.43), male gender (odds ratio, 4.05; 95% confidence interval, 1.82-9.02) and immunosuppressive exposure at the index date (odds ratio, 4.20; 95% confidence interval, 1.35-13.11) were significantly associated with increased odds of developing lymphoma. Disease severity and use of anti-tumor necrosis factor agents were not independently associated with developing lymphoma. When testing was performed on patients exposed to immunosuppressive or anti-tumor necrosis factor medications, Epstein-Barr virus was identified 75% of the time.Conclusions:In this case-control study, increasing age, male gender, and use of immunosuppressive medications were associated with an increased risk of lymphoma in patients with IBD.
引用
收藏
页码:1384 / 1389
页数:6
相关论文
共 50 条
  • [31] Lymphoma risk in inflammatory bowel disease: Is it the disease or its treatment?
    Jones, Jennifer L.
    Loftus, Edward V., Jr.
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (10) : 1299 - 1307
  • [32] Small intestinal bacterial overgrowth in patients with inflammatory bowel disease: A case-control study
    Uday C. Ghoshal
    Ankur Yadav
    Bushra Fatima
    Anand Prakash Agrahari
    Asha Misra
    Indian Journal of Gastroenterology, 2022, 41 : 96 - 103
  • [33] Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAID
    Reenaers, Catherine
    de Roover, Arnaud
    Kohnen, Laurent
    Nachury, Maria
    Simon, Marion
    Pourcher, Guillaume
    Trang-Poisson, Caroline
    Rajca, Sylvie
    Msika, Simon
    Viennot, Stephanie
    Alttwegg, Romain
    Serrero, Melanie
    Seksik, Philippe
    Peyrin-Biroulet, Laurent
    Picon, Laurence
    Tournois, Celine Bourbao
    Gontier, Renaud
    Gilletta, Cyrielle
    Stefanescu, Carmen
    Laharie, David
    Roblin, Xavier
    Nahon, Stephane
    Bouguen, Guillaume
    Carbonnel, Franck
    Attar, Alain
    Louis, Edouard
    Coffin, Benoit
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (08) : 1198 - 1206
  • [34] Small intestinal bacterial overgrowth in patients with inflammatory bowel disease: A case-control study
    Ghoshal, Uday C.
    Yadav, Ankur
    Fatima, Bushra
    Agrahari, Anand Prakash
    Misra, Asha
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2022, 41 (01) : 96 - 103
  • [35] Previous Cancer/Lymphoma and Refractory Inflammatory Bowel Disease
    Bernheim, Oren
    Axelrad, Jordan
    Itzkowitz, Steven H.
    Colombel, Jean-Frederic
    DIGESTIVE DISEASES, 2015, 33 : 44 - 49
  • [36] Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study
    Losurdo, Giuseppe
    La Fortezza, Rosa Federica
    Iannone, Andrea
    Contaldo, Antonella
    Barone, Michele
    Ierardi, Enzo
    Di Leo, Alfredo
    Principi, Mariabeatrice
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (47) : 7528 - 7537
  • [37] Risk factors for malignancy and serious infection in patients with inflammatory bowel disease: a retrospective analysis
    Tassone, Daniel
    Basnayake, Chamara
    Wright, Emily
    Lust, Mark
    Kamm, Michael A.
    Niewiadomski, Ola
    Schulberg, Julien
    Flanagan, Emma
    Samyue, Tamie
    Fry, Stephanie
    Malcolm, Ruth
    Stanley, Annalise
    Thompson, Alexander J.
    Connell, William R.
    Ding, Nik S. S.
    INTERNAL MEDICINE JOURNAL, 2024, 54 (03) : 446 - 454
  • [38] Environmental factors in inflammatory bowel disease: A case-control study based on a Danish inception cohort
    Hansen, Tanja Stenbaek
    Jess, Tine
    Vind, Ida
    Elkjaer, Margarita
    Nielsen, Malene Fey
    Gamborg, Michael
    Munkholm, Pia
    JOURNAL OF CROHNS & COLITIS, 2011, 5 (06) : 577 - 584
  • [39] Incidence and Risk Factors for Lymphoma in a Single-Center Inflammatory Bowel Disease Population
    Chiorean, Michael V.
    Pokhrel, Bhupesh
    Adabala, Jaya
    Helper, Debra J.
    Johnson, Cynthia S.
    Juliar, Beth
    DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (05) : 1489 - 1495
  • [40] Common variation in the vitamin D receptor gene and risk of inflammatory bowel disease in an Irish case-control study
    Hughes, David J.
    McManus, Ross
    Neary, Paul
    O'Morain, Colm
    O'Sullivan, Maria
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 23 (09) : 807 - 812